Breast Cancer has Pharmas Largest and Most Innovative Drug Pipeline, says GBI Research
The breast cancer therapeutics pipeline boasts a high degree of innovation in first-in-class molecules, with many new technologies holding the potential to transform the clinical and commercial treatment landscape during the coming decade, says business intelligence provider GBI Research.
The company’s latest report* states that breast cancer has the largest drug pipeline in the pharmaceutical industry, with 816 products in active development across all stages. Of these treatments, GBI Research has identified 245 first-in-class programmes acting on 175 first-in-class molecular targets, accounting for 39% of all products with a disclosed molecular target.
Dominic Trewartha, Analyst for GBI Research, says: “The mechanisms of action in the breast cancer pipeline cover an extremely diverse range. Traditional chemotherapies and hormone therapies, for example, represent just 22% of the total pipeline, and there is an increasing move towards developing therapies that directly target proliferative signaling pathways. These therapies account for 31% of the pipeline.”
According to GBI Research, the most widely studied, first-in-class targets in the breast cancer pipeline are signal transducer proteins. These are components of proliferative and survival-promoting signaling pathways, such as Ras/MAPK and PI3K/Akt, which operate downstream of the receptor. It is now understood that these agents share a high degree of crosstalk with one another.
Trewartha continues: “Most first-in-class products in the breast cancer pipeline currently reside between the discovery and preclinical stages of development, although there are some in Phase I through to Phase III.
“Despite the high failure rates witnessed in clinical trials, many first-in-class products will reach the market within the next decade, providing new therapies to currently underserved patient segments with significant unmet needs.”
GBI Research also states that the challenge to develop products targeting novel rather than well-established pathways is offset by the real potential to discover highly effective drugs, which could alter the treatment market dynamics, increase competition and help drive further therapeutic innovation in breast cancer.
*Frontier Pharma - Breast Cancer - Identifying and Commercializing First-in-Class Innovation
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance